Newsletter · · Ashutosh Agarwal

AstraZeneca's CFO Confirms the Most Favored Nation Deals Are Signed - Drug Pricing & IRA Round 2 Weekly - Week of August 10, 2026

For the week of August 3 to 10, 2026, AstraZeneca's chief financial officer became the first named operator to confirm the Most Favored Nation deals are signed and to describe how they work, while the Part D subsidy sunset got numbers that landed below what carriers hoped.

Drug Pricing & IRA Round 2 Weekly

Week of August 10, 2026: AstraZeneca's CFO Confirms the Most Favored Nation Deals Are Signed

  • A Big Pharma finance chief said the quiet part out loud: yes, we signed. For months, "Most Favored Nation" (MFN) pricing has been a Trump-administration threat and a stack of press releases. This week the chief financial officer of AstraZeneca, a genuine company insider, sat down with Barron's and plainly described the deal her company and others have already signed: the US government (Medicare, Medicaid) will now get net drug prices "at par with other wealthy nations… on a GDP-adjusted basis." That is the first time in this letter's memory that a named operator has confirmed the MFN agreements are inked, not just floated, and framed them as a permanent feature of how new US drugs get priced. (At Barron's)

  • The single biggest fight in obesity is really a fight about the IRA clock. Eli Lilly used its earnings call to double down on a plan to get its next weight-loss drug, retatrutide, classified as a biologic rather than a small-molecule pill, a distinction that decides whether the government can force price cuts after 9 years or 13. Lilly lost the first round in court, is appealing (first hearing September 24 in Chicago), and still says it will file the biologic application in the first quarter. This is the "pill penalty" debate wearing a lab coat, and it has a real date on the calendar. (On The Pen GLP-1 News)

  • Last week's Part D subsidy story got hard numbers, and they're worse than the industry hoped. Medicare insurance brokers walked through the just-released figures confirming the temporary cushion for stand-alone drug plans is ending: the government's per-member subsidy came in at $255, "far below industry expectations," so premiums on those plans "are about to go up quite substantially." And a striking stat on how fast people now blow through their drug budget: the share of seniors hitting Medicare's most expensive coverage tier jumped from 1.4% in June 2023 to 6.4% in June 2025. (The Broker Link)

  • Lilly's obesity machine printed a huge quarter, while cutting prices. Its two big drugs did roughly $15 billion in a single three-month stretch, with net prices down about 13% even as volume rose ~60%. Lilly now controls roughly 60% of the US obesity/diabetes market to Novo Nordisk's ~39%. The takeaway for pricing: the volume land-grab is so large that the companies are willingly giving up price to win it. (The Rundown; On The Pen GLP-1 News)

  • A possible mega-merger surfaced: the Financial Times reported AstraZeneca is in talks to buy Bristol-Myers Squibb, a roughly $400 billion combination that would still be less than half the size of Lilly. Note the drug-pricing tell buried in the CNBC chatter: if they ever want it approved, "you lead with… lowering drug prices." (Squawk on the Street)

  • Honest note on what was quiet: no podcast this week touched the actual IRA Round 2 timeline (2027 talks, 2028 prices), the 2028 selected-drug list adding Part B drugs, the EPIC Act, 340B, or the generic-tariff clock we covered last week, and, once again, nobody put a revenue-at-risk number on Eliquis, Keytruda, Stelara, or the other tracked franchises. This was an obesity-and-MFN week, told mostly through earnings.

What's new

Ranked by how much a hedge-fund book can act on it.

1. An AstraZeneca insider confirms the MFN deals are signed: and describes exactly how they work

Most of what this letter tracks about "Most Favored Nation" pricing comes filtered through politicians, press releases, and pundits. This week we got it straight from the person who has to model it. On an August 6 episode of At Barron's, AstraZeneca's chief financial officer, a bona fide operator/insider, the person who signs off on where the company's R&D dollars go, was asked directly about "governments looking to curb drug pricing." Her answer was matter-of-fact.

First, a plain-English definition, because "MFN" gets thrown around loosely. It means the US refuses to keep paying far more than everyone else. In the CFO's words:

"The MFN is an agreement we and other pharma companies signed, which is relating to most favored nations. So the U.S. government, so Medicare, Medicaid, etc., will get pricing for drugs, net pricing for drugs, that is at par with other, you know, wealthy nations and on a GDP-adjusted basis."

Three things make this notable for a book. One, the tense: "an agreement we… signed." Not proposed, not threatened, signed, and spoken of as settled. Two, the mechanism she describes is a net price (what's actually collected after rebates and discounts) benchmarked to other rich countries and adjusted for how wealthy each one is, which is a very different, and generally deeper, cut than a simple list-price comparison. Three, her spin on it, which tells you how management wants investors to think about it: she argued MFN "obviously helps over time lower costs for new drugs coming into the U.S. market," but that the real prize is prying money loose overseas, "it also forces countries to invest more in their innovative medicines," a case she says AstraZeneca is "making to many of these countries in Europe because they have underinvested." (At Barron's)

She was also refreshingly candid that this is now the permanent backdrop to capital allocation. Asked how she picks which drugs to fund, she listed the usual, unmet need, how "de-risked" the science is, and then added "the financial and pricing and how the landscape may evolve in five years from now when you actually end up launching the product." Translation: MFN and negotiation are now baked into the go/no-go math on every early-stage program. On tariffs and US manufacturing, she was relaxed: AstraZeneca is "probably more blessed than many," pointing back to the 3 billion-plus COVID vaccine doses it produced globally as evidence of a distributed supply chain.

Why it matters for a book: this is the clearest operator confirmation to date that the MFN framework is a done deal for at least some large drugmakers, that it bites on net not list prices, and that management is already framing the offset as "make Europe pay more" rather than "absorb the US hit." Whether that offset actually materializes is the whole ballgame, and it's a multi-year story, not a next-quarter one.

2. The retatrutide "biologic vs. pill" fight is the pill-penalty debate with a court date

Here's the most underappreciated policy story in obesity, and it ran straight through Lilly's earnings call. On an August 7 recap from On The Pen GLP-1 News, a patient-focused show (pundit/advocate, but unusually deep on the regulatory weeds), the host laid out why Lilly is fighting so hard to have its next-generation drug, retatrutide, labeled a biologic instead of a small molecule.

The plain-English stakes: under the IRA, the government can start forcing price cuts on small-molecule drugs (ordinary pills) 9 years after approval, but on biologics (complex drugs grown in living cells) only after 13 years. That four-year gap, the very thing the "pill penalty" debate is about, is worth billions on a drug this size. Classification also changes how long before cheap copycats can arrive and which approval pathway applies. As the host put it, this fight "would have ripple effects for every single GLP-1 that comes down the pipeline… if they say retatrutide mimics a bodily function and is an analogous protein, then the rest of them that come down the pike certainly are too."

What actually happened this week: Lilly lost the first round, the FDA said retatrutide is not a biologic, and a court agreed. But CEO David Ricks used the call to double down, saying Lilly still believes retatrutide qualifies "both in terms of the amino acid count rule… as well as the analogous-to-a-protein rule," and that the company plans to submit its biologics application in the first quarter, with the clinical data "already largely ready." Lilly's appeal hearing is scheduled for September 24 in Chicago. The host's shrewd read: the fact that Lilly gave the designation back to the FDA and then appealed, rather than simply letting the agency reconsider, suggests Lilly itself isn't sure the FDA is in its corner, even as "open dialogue" continues behind the litigation. (On The Pen GLP-1 News)

Why it matters for a book: this is a rare case where the abstract "small-molecule vs. biologic" pricing debate has a specific, near-term catalyst (the September 24 hearing) attached to a mega-cap's most important pipeline asset. A biologic ruling means a longer runway before IRA negotiation can touch retatrutide; a small-molecule ruling pulls that clock four years earlier and, by the host's logic, sets a precedent that reaches across the whole GLP-1 class.

3. The Part D subsidy sunset gets its numbers: and they land below what carriers hoped

Last week we flagged that the government is ending, a year early, the temporary program that softened the blow of the IRA's new out-of-pocket cap for stand-alone Medicare drug plans. This week the hard figures dropped, and two Medicare insurance brokers, field operators who sell these plans for a living, walked through them on the August 4 episode of The Broker Link.

Quick translation of the jargon: every year the government sets a benchmark called the NAMBA (national average monthly bid amount) that drives how much it pays drug-plan insurers. Subtract the standard premium enrollees pay, and what's left is the "direct subsidy" the government kicks in per member. This year:

  • The NAMBA came in at $296.05, the base premium at $41.33, leaving a direct subsidy of $255, which the brokers called "far below industry expectations."

  • Because the stabilization cushion is going away, "costs on stand-alone Part D are about to go up quite substantially," and they expect insurers to trim Medicare Advantage benefits too, since the subsidy "came in lower than expectations."

The most eye-opening stat was about how fast seniors now hit Medicare's priciest coverage phase (the "catastrophic" tier, where the government picks up most of the cost). Thanks to a quirk in how spending is counted, "a non-low-income beneficiary is hitting the catastrophic phase by only spending $1,220 out of pocket", well below the headline ~$2,100 cap, and the share of enrollees reaching that phase has more than quadrupled, from 1.4% in June 2023 to 6.4% in June 2025. The brokers were blunt about the losers: the people shouldering the pain are "the non-low-income Part D beneficiaries," so "more are suffering than are benefiting" from the IRA's redesign. (The Broker Link)

The same episode carried a genuinely bullish signal for one tracked name. Steve Nelson, an executive vice president of CVS Health and president of its Aetna unit (an operator/insider), told the brokers that Medicare Advantage is "one of the most important assets managed by CVS Health," that the company is "not backing away," and pointed to a committed $20 billion technology investment over the next 10 years. After a brutal year of managed-care fear, a CVS leader planting a flag in Medicare Advantage is worth noting. (The Broker Link)

Why it matters for a book: this is the read-through that has an actual dollar figure. A $255 direct subsidy and a quadrupling of catastrophic-phase enrollees both point the same direction, the economics of stand-alone drug plans and Medicare Advantage are tightening as the IRA's redesign fully bites, with the cost landing on middle-income seniors and, by extension, the insurers who cover them.

4. Lilly's blowout quarter shows the pricing trade the whole industry is making

For a picture of how drug pricing is actually behaving inside the hottest category in pharma, the August 6 episode of The Rundown (a business-news show, pundit) had the cleanest numbers. Lilly's two GLP-1 drugs, Mounjaro (diabetes) and Zepbound (weight loss), did roughly $15 billion combined in a single quarter: Mounjaro about $9.9 billion (up 91% year over year) and Zepbound about $4.9 billion (up 46%). The pricing detail is the point: net prices fell about 13%, but volume rose roughly 60%, and Lilly now holds about 60% of the US obesity/diabetes market versus Novo Nordisk's ~39%. (The Rundown)

On The Pen filled in the same picture from the earnings call: Mounjaro plus Zepbound at $14.9 billion for the quarter, up $6.3 billion year over year; the US "incretin" (GLP-1) market up 78%; the international market up 74%. And a data point that says a lot about willingness to pay: 45% of all Zepbound prescriptions, and 55% of new ones, are self-pay, i.e., people writing a roughly $450-a-month check with no insurance help. (On The Pen GLP-1 News)

Why it matters for a book: it reframes the pricing debate. In the category everyone worries the government will eventually negotiate, the makers are voluntarily cutting net price to grab share, and demand is so strong that nearly half of patients pay cash. That is a very different risk profile from a legacy pill whose entire value rests on a protected list price.

5. Odds and ends worth a line

  • Employers are the quiet whale in GLP-1 demand. Two shows this week, Morning Brew Daily (August 7) and Frequency (August 10), flagged that Bank of America is spending roughly $250 million a year on GLP-1 drugs for its employees, and framed the growing tension in company health plans between workers who want coverage and colleagues who resent footing the shared bill. It's a reminder that a huge slice of GLP-1 volume runs through employer plans, not Medicare, the exact channel MFN and IRA negotiation don't directly touch. (Morning Brew Daily; Frequency)

  • Cost is still the number-one reason people quit these drugs. On the August 3 Primary Care Update, a clinician noted he routinely sees patients lose serious weight on a GLP-1 and then stop "because of cost, insurance coverage", and discussed a Lilly-funded trial testing whether a lower maintenance dose could keep the weight off for less money. Affordability, not efficacy, is the binding constraint at the patient level. (Primary Care Update)

The debate

The core argument this letter tracks, manageable, modeled headwind versus structural US margin compression, didn't get a fresh IRA Round 2 data point this week, but the MFN confirmation and the retatrutide fight sharpened both sides.

"It's a bounded, well-flagged headwind that management is already pricing in, and the real fix is making Europe pay." The bull case got its best spokesperson this week in AstraZeneca's CFO, who described MFN not as an emergency but as a known input she already bakes into five-year investment decisions, and reframed it as leverage to force higher drug spending in Europe rather than a permanent hit to US margins. Add Lilly's quarter: in the category most exposed to future negotiation, the makers are giving up ~13% on net price by choice to win 60%-plus volume growth, with nearly half of patients paying cash, hardly a company cornered on price. And CVS's leadership publicly recommitting $20 billion to Medicare Advantage suggests the managed-care players see a floor, not a cliff. (At Barron's; The Rundown; The Broker Link)

"The squeeze is real, permanent, and now hitting net prices and the middle-income patient at once." The bear reading: MFN is signed, it cuts net prices (the ones that actually matter) against a GDP-adjusted foreign benchmark, and the promised European offset is a hope, not a contract. Meanwhile the IRA's Part D redesign is landing exactly where the brokers said it would, a $255 direct subsidy well below expectations, premiums set to rise "substantially," and a quadrupling of seniors blowing through to the catastrophic tier on as little as $1,220 out of pocket. And the retatrutide fight shows the whole industry now has to litigate to preserve pricing runway on its best assets; if Lilly loses and retatrutide is a small molecule, the negotiation clock on the entire next GLP-1 generation moves four years closer. (At Barron's; The Broker Link; On The Pen GLP-1 News)

The swing factor this week is classification, not legislation. Congress didn't move on the EPIC Act or Round 2 this week. But the September 24 retatrutide appeal is a live, dated event that functions as a real-world referendum on the pill-penalty problem, and a small-molecule ruling would be a broader, precedent-setting negative than any single franchise number.

Stocks in play

Straight talk, same as prior weeks: no podcast this week attached a franchise-level revenue-at-risk figure to Eliquis, Keytruda, Stelara, Imbruvica, Xarelto, Jardiance, Farxiga, Tagrisso, Pomalyst, or Venclexta. What follows is only what the week's episodes actually implied.

Eli Lilly (LLY), the week's most-discussed name.

  • Bull: a ~$15 billion GLP-1 quarter with 60%-plus volume growth and ~60% US market share; nearly half of Zepbound scripts are self-pay at ~$450/month, showing pricing power the negotiation regime can't easily touch; the obesity and non-obesity pipeline is seen as ahead of Novo's.
  • Bear/uncertainty: net prices are already falling ~13%, and the retatrutide biologic classification is unresolved, a small-molecule ruling pulls the IRA negotiation clock four years earlier on a flagship asset.
  • Next catalyst / number to watch: the September 24 retatrutide appeal hearing in Chicago, and whether Lilly actually files the biologics application in Q1 as promised. (On The Pen GLP-1 News; The Rundown)

Novo Nordisk (NVO), the contested value name.

  • Bull: on CNBC's Fast Money, one holder argued Novo is "a much more interesting story… on valuation," with a heavily discounted management team and under-appreciated execution on the Wegovy pill rollout, a setup where sentiment is washed out.
  • Bear: the same desk conceded that whatever Lilly reported, "Novo will trade down" on the read-through; Novo holds the smaller ~39% share and faces persistent questions about management turnover, "very poor communication," and whether its pipeline can keep pace with Lilly's triple-agonist.
  • Next to watch: any read-through from Lilly's retatrutide classification (it shapes the rules for Novo's own next-gen candidates), and evidence of a real management reset. (CNBC's "Fast Money")

AstraZeneca (AZN), the MFN and M&A name.

  • Bull: management publicly frames MFN as manageable and already modeled, claims a tariff-resilient, distributed supply chain, and is reportedly hunting scale via a potential Bristol-Myers deal.
  • Bear: it has now signed an agreement that cuts US net prices toward foreign benchmarks; the "Europe will pay more" offset is unproven; and a large, oncology-heavy merger would draw pricing-and-antitrust scrutiny.
  • Next to watch: any confirmation, denial, or terms around the Bristol-Myers talks. (At Barron's; Squawk on the Street)

Bristol-Myers Squibb (BMY), the target.

  • Bull: the FT-reported AstraZeneca interest puts a potential takeout bid under the stock; its oncology franchise is the strategic draw.
  • Bear: shares slid from $70.50 to $67 after the report on an "okay quarter, not a great quarter"; nothing is confirmed, and a deal this size faces a long regulatory road.
  • Next to watch: confirmation of the talks, and whether "we'll lower drug prices" becomes the deal's public pitch. (Squawk on the Street)

CVS Health (CVS), the managed-care read-through with a rare bullish tell.

  • Bull: a CVS EVP called Medicare Advantage "one of the most important assets" the company manages, said CVS is "not backing away," and pointed to a $20 billion, 10-year tech commitment.
  • Bear: the Part D subsidy sunset and the below-expectations $255 direct subsidy still tighten the economics of the drug-plan business CVS runs.
  • Next to watch: fall 2027 bid and premium disclosures. (The Broker Link)

JNJ, PFE, MRK, ABBV, no company-specific podcast commentary this week. All carry blockbusters exposed to negotiation and MFN, and PFE was mentioned only in passing (it "dropped a couple of obesity candidates" this week, per On The Pen). Franchise-level numbers will have to come from filings and Street models; the podcasts didn't provide them, and I won't manufacture them.

Read-throughs

Big Pharma with MFN exposure (AZN, and by extension JNJ, PFE, MRK, BMY, ABBV, LLY, NVO). The AstraZeneca CFO's confirmation matters beyond one company: it establishes that these agreements are signed, that they cut net prices against a GDP-adjusted rich-country benchmark, and that management's playbook is to argue Europe must pay more rather than absorb the US hit. Every large drugmaker with a big US Medicare/Medicaid book now sits under the same framework; the differentiator is whether a given company can credibly extract the offshore offset. (At Barron's)

Small-molecule vs. biologic mix (LLY first, then the whole GLP-1 class). The retatrutide case is the cleanest live example of why the "pill penalty" matters: the same molecule is worth materially more with 13 years of IRA protection than with 9. A ruling either way ripples to every follow-on GLP-1 and to how companies design future assets, favoring biologic formats precisely because they buy time before negotiation. Watch September 24. (On The Pen GLP-1 News)

PBMs / managed care (CVS, CI, UNH, and Part D insurers incl. Humana). The Broker Link is the operator's-eye view of the same subsidy-sunset story we opened last week, now with numbers. A $255 direct subsidy "far below industry expectations," premiums set to rise "substantially," and catastrophic-phase enrollment quadrupling to 6.4% all point to a tighter drug-plan and Medicare Advantage setup in 2027. The offsetting signal is CVS's explicit recommitment to Medicare Advantage and $20 billion of tech spend, a reminder these are diversified players choosing to lean in, not flee. (The Broker Link)

GLP-1 volume vs. price (LLY, NVO, employer channel). The clearest structural read of the week: in the drug class most exposed to future negotiation, net prices are already falling while volumes explode, nearly half of demand is cash-pay, and a big chunk of the rest flows through employer plans (Bank of America's ~$250 million/year) that MFN and IRA negotiation don't directly reach. Price risk in obesity is more a function of competition and share wars than of the government, for now. (The Rundown; Morning Brew Daily)

Biosimilar / generic makers (TEVA, Indian exporters). No coverage this week, last week's generic-tariff clock (100% from August 2028) drew no fresh podcast discussion. The screen from last week (who already owns US manufacturing capacity) is unchanged but got no new data.

What changed vs. last week

Last week (July 27 – Aug 3) was middlemen and clocks, a PBM reform bill clearing a House committee 40-2, a firm generic-tariff timeline, the GLP-1 "BRIDGE" pilot fully spec'd, and the Part D subsidy sunset first surfacing. This week was obesity and MFN, told through earnings, and it moved the ball on two fronts that last week only teased.

What moved:

  • MFN went from threat to signed fact, confirmed by an operator. Last week MFN was administration pressure; this week AstraZeneca's CFO described the agreement as already signed and explained the net-price, GDP-adjusted mechanism on the record. That's a real upgrade in evidence quality. (At Barron's)
  • The pill-penalty debate got a company, an asset, and a court date. The retatrutide biologic-vs-small-molecule fight is the most concrete version of this debate we've seen, with a September 24 appeal hearing and a promised Q1 biologics filing. (On The Pen GLP-1 News)
  • Last week's Part D subsidy story got its numbers. The direct subsidy landed at $255 (below expectations), premiums are set to rise "substantially," and catastrophic-phase enrollment has quadrupled to 6.4%, plus a genuinely bullish CVS/Aetna recommitment to Medicare Advantage. (The Broker Link)
  • Last week's earnings preview resolved. The Novo/Lilly reports we flagged for "this coming Wednesday" happened: Lilly delivered a ~$15 billion GLP-1 quarter with net prices down ~13% and ~60% market share, and the Novo-vs-Lilly value debate rolled on. (The Rundown; CNBC's "Fast Money")
  • A new M&A thread opened: the FT-reported AstraZeneca–Bristol-Myers talks. (Squawk on the Street)

What did not move (still quiet): no coverage of the IRA Round 2 negotiation timeline (2027 talks, 2028 prices); nothing on the 2028 selected-drug list or its first-ever Part B inclusion; nothing on the EPIC Act text or 340B; no fresh generic-tariff discussion; and no franchise-level revenue-at-risk numbers on JNJ, PFE, MRK, BMY, or ABBV. Those remain the threads to watch for a true Round 2 "what changed."